NICE approves immunotherapy combo for certain untreated advanced kidney cancer patients
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for patients with previously untreated advanced renal cell carcinoma (RCC) that is intermediate- or poor-risk, US pharma major Bristol Myers Squibb (NYSE: BMY) has revealed.
In appraising the treatment, the NICE considered additional data collected since 2019 through the Cancer Drugs Fund, as well as data from the Checkmate-214 trial.
The decision is supported by five-year data from the Checkmate-214 trial, which showed improved overall survival (OS) and overall response rates (ORR) compared to sunitinib. The NICE decision means the combination will continue to be a treatment option for patients diagnosed with intermediate- or poor-risk advanced RCC in England.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze